InvestorsHub Logo
Followers 4
Posts 1198
Boards Moderated 0
Alias Born 10/03/2015

Re: None

Friday, 01/15/2021 12:39:50 PM

Friday, January 15, 2021 12:39:50 PM

Post# of 932
TIL not so effective. ORR = 33% at 6 months

• Efficacy for 9 HNSCC patients treated with LN-145 therapy + lymphodepletion + IL2 + naive pembrolizumab:

– 11.1 % CR
– 44.4 % ORR